-
CRT Downgrades BorgWarner To Neutral
Tuesday, February 16, 2016 - 11:19am | 224CRT issued a company report on BorgWarner, Inc. (NYSE: BWA) after the company reported financial results that were below expectations for the fourth quarter. The firm downgraded BorgWarner from Buy to Neutral and issued a $40 price target. Analysts Michael Ward and Ali Faghri wrote, "...
-
Yahoo Remains 'Focus Pick' For CRT Capital Despite Aabaco Tax Drama
Monday, July 20, 2015 - 1:26pm | 320In a recent report, CRT Capital analyst Robert Coolbrith reiterated a Buy rating and $61.00 price target on Yahoo! Inc. (NASDAQ: YHOO). The Spinoff Last Friday, Yahoo filed an initial registration statement for the spinoff of its large stake in China's Alibaba Group Holding Ltd (NYSE...
-
CRT Capital Upgrades United Continental To Buy, Sees Merger Integration In 'Seventh Inning'
Monday, July 6, 2015 - 11:26am | 244In a report published Monday, CRT Capital analyst Michael Derchin upgraded the rating on United Continental Holdings Inc (NYSE: UAL) from Fair Value to Buy, with a price target of $70. United Continental is focusing on improving its margins, generating more cash flows and enhancing its core...
-
CRT Capital Upgrades United Continental To Buy
Monday, July 6, 2015 - 9:31am | 55CRT Capital upgraded United Continental Holdings Inc (NYSE: UAL) from Fairly Valued to Buy. United Continental shares have gained 33.35 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. United Continental shares rose 0.89 percent to $51.94 in...
-
CRT Capital Initiates Coverage On Ultragenyx Pharmaceutical
Wednesday, March 25, 2015 - 2:00pm | 160CRT Capital on Wednesday initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) after the company has made strides toward commercializing its products. CRT Capital rates Ultragenyx as a Buy with a $90 price target. Analyst Carol Werther wrote, "Six programs are in Phases 2 or 3 of the...
-
CRT Raises JetBlue Price Target, Says 2015 Could Be Year Investors Have Been Waiting For
Tuesday, March 24, 2015 - 10:55am | 164CRT Capital issued a note on JetBlue Airways Corporation (NASDAQ: JBLU) as the airline attempts to narrow the margin gap with its competitors. CRT Capital rates JetBlue as a Buy and raised its price target from $22 to $24. Analyst Michael Derchin wrote, "The $64 question for Buy-rated JetBlue...
-
Here's Why CRT Capital Upgraded Pandora
Wednesday, March 18, 2015 - 10:45am | 231Shares of Pandora Media Inc (NYSE: P) were up more than 4 percent on Wednesday. CRT Capital analysts Robert Coolbrith and Shweta Khajuria upgraded the stock to Buy and raised their price target from $16 to $22. The price target reflects the average of their bull-case and worst-case valuation...
-
CRT Capital Upgrades Pandora Media To Buy
Wednesday, March 18, 2015 - 8:45am | 59CRT Capital upgraded Pandora Media, Inc. (NYSE: P) to Buy. The price target for Pandora Media has been raised from $16.00 to $22.00. Pandora Media shares have dropped 54.94% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period. Pandora Media's shares rose 2.67%...
-
US Stock Futures Down; All Eyes On Fed Decision
Wednesday, March 18, 2015 - 7:24am | 414Pre-open movers US stock futures traded lower in early pre-market trade. The Federal Open Market Committee will announce its policy decision at 2:00 p.m. ET, while the Fed Chairwoman Janet Yellen will hold a press conference at 2:30 p.m. ET. Futures for the Dow Jones Industrial Average declined 63....
-
CRT Capital Initiates B/E Aerospace With Buy
Tuesday, March 17, 2015 - 8:01am | 67Analysts at CRT Capital initiated coverage on B/E Aerospace Inc. (NASDAQ: BEAV) with a Buy rating. The target price for B/E Aerospace is set to $73. B/E Aerospace shares have dropped 3.52% over the past 52 weeks, while the S&P 500 index has surged 11.16% in the same period. B/E Aerospace shares...
-
Why Valeant, Not Endo, Could Still Win The War For Salix
Thursday, March 12, 2015 - 1:54pm | 344As reported on Wednesday, Endo International PLC (NASDAQ: ENDP) has made a takeover bid for Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), even though Valeant Pharmaceuticals Intl Inc (NYSE: VRX) already has an agreement to purchase the latter for roughly $10 billion. Sources familiar with the issue...
-
CRT Capital Upgrades Skullcandy To Buy
Friday, March 6, 2015 - 8:43am | 60Analysts at CRT Capital upgraded Skullcandy, Inc. (NASDAQ: SKUL) from Fairly Valued to Buy. The price target for Skullcandy has been raised from $9 to $13. Skullcandy shares have jumped 19.93% over the past 52 weeks, while the S&P 500 index has gained 11.87% in the same period. Skullcandy's...
-
UPDATE: CRT Capital Upgrades Sturm, Ruger & Company As Industry Outlook Continues To Improve
Thursday, March 5, 2015 - 10:28am | 146In a report published Thursday, CRT Capital analyst Brian Ruttenbur upgraded the rating on Sturm, Ruger & Company (NYSE: RGR) from Fair Value to Buy, and raised the price target from $54.00 to $62.00. In the report, CRT Capital noted, "We have increased our price target on shares of RGR to $62...
-
CRT Capital Initiates Ligand Pharmaceuticals With Buy
Tuesday, March 3, 2015 - 10:24am | 61CRT Capital initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with a Buy rating. The target price for Ligand Pharmaceuticals is set to $102. Ligand Pharmaceuticals shares have dropped 13.54% over the past 52 weeks, while the S&P 500 index has surged 12.99% in the same...
-
Zillow: 2 Analysts Weigh In With 2 Widely Different Views
Friday, February 20, 2015 - 1:11pm | 486Analysts from CRT Capital and JMP Securities on Thursday weighed in on earnings and revised its price targets for the freshly named Zillow Group Inc (NYSE: Z), reflecting its merger with Trulia. There was a significant difference between the revised price targets updated by these two firms...